{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:11:26Z","timestamp":1774714286743,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.berh.2021.101720","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T18:53:45Z","timestamp":1635447225000},"page":"101720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Calcium pyrophosphate deposition (CPPD) disease \u2013 Treatment options"],"prefix":"10.1016","volume":"35","author":[{"given":"John","family":"Stack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.berh.2021.101720_bib1","doi-asserted-by":"crossref","first-page":"563 LP","DOI":"10.1136\/ard.2010.139105","article-title":"European League against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semarthrit.2020.10.005","article-title":"Management of calcium pyrophosphate crystal deposition disease: a systematic review","volume":"51","author":"Parperis","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101720_bib3","first-page":"327","article-title":"Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD","volume":"23","author":"Rothschild","year":"1997","journal-title":"Compr Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: No significant effect in a randomized crossover trial","volume":"16","author":"Finckh","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2021.101720_bib5","doi-asserted-by":"crossref","first-page":"106 LP","DOI":"10.1136\/ard.42.Suppl_1.106","article-title":"Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy","volume":"42","author":"Doherty","year":"1983","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2021.101720_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: Management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101720_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41584-018-0078-5","article-title":"Calcium crystal deposition diseases \u2014 beyond gout","volume":"14","author":"McCarthy","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2021.101720_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/01.mjt.0000433937.07244.e1","article-title":"Colchicine: new insights to an old drug","volume":"22","author":"Stack","year":"2015","journal-title":"Am J Therapeut"},{"issue":"4","key":"10.1016\/j.berh.2021.101720_bib9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2021.101720_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/0003-4819-81-6-792","article-title":"Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study","volume":"81","author":"Goldstein","year":"1974","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.berh.2021.101720_bib11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJM197410312911804","article-title":"Colchicine therapy for familial mediterranean fever. A double-blind trial","volume":"291","author":"Dinarello","year":"1974","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.berh.2021.101720_bib12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/archinte.165.17.1987","article-title":"Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial","volume":"165","author":"Imazio","year":"2005","journal-title":"Arch Intern Med"},{"issue":"7081","key":"10.1016\/j.berh.2021.101720_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.berh.2021.101720_bib14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1973.03230010020004","article-title":"Pseudogout syndrome in hospital patients","volume":"226","author":"O'Duffy","year":"1973","journal-title":"J\u00a0Am Med Assoc"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jbspin.2013.05.006","article-title":"ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients","volume":"81","author":"Daoussis","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.berh.2021.101720_bib17","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.berh.2021.101720_bib19","first-page":"1001","article-title":"Biologics in the treatment of calcium pyrophosphate deposition disease: systematic literature review","volume":"38","author":"Cipolletta","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2021.101720_bib20","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101720_bib21","doi-asserted-by":"crossref","first-page":"679 LP","DOI":"10.1136\/annrheumdis-2019-216821","article-title":"2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews","volume":"79","author":"Nash","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2021.101720_bib22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/annrheumdis-2015-207487","article-title":"Interleukin-6 and chondrocyte mineralisation act in tandem to promote experimental osteoarthritis","volume":"75","author":"Nasi","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2021.101720_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101720_bib24","doi-asserted-by":"crossref","first-page":"1126 LP","DOI":"10.1136\/annrheumdis-2020-217188","article-title":"Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study","volume":"79","author":"Latourte","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2021.101720_bib25","doi-asserted-by":"crossref","first-page":"456 LP","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101720_bib26","doi-asserted-by":"crossref","first-page":"14 LP","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101720_bib27","series-title":"Osteoarthritis: care and management","year":"2020"},{"issue":"24","key":"10.1016\/j.berh.2021.101720_bib28","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1056\/NEJMp1710014","article-title":"Coupling policymaking with evaluation -- the case of the opioid crisis","volume":"377","author":"Barnett","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2021.101720_bib29","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.40517","article-title":"Review: unmet needs and the path forward in joint disease associated with calcium pyrophosphate crystal deposition","volume":"70","author":"Abhishek","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"8258","key":"10.1016\/j.berh.2021.101720_bib30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(81)91488-4","article-title":"Effect of intra-articular YTTRIUM-90 on chronic pyrophosphate arthropathy of the knee","volume":"318","author":"Doherty","year":"1981","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2021.101720_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/pho.2006.24.140","article-title":"Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results","volume":"24","author":"Soriano","year":"2006","journal-title":"Photomed Laser Surg"},{"issue":"10055","key":"10.1016\/j.berh.2021.101720_bib32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.berh.2021.101720_bib33","doi-asserted-by":"crossref","first-page":"18920","DOI":"10.1074\/jbc.272.30.18920","article-title":"Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway","volume":"272","author":"Nair","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"10.1016\/j.berh.2021.101720_bib34","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/rheumatology\/key092","article-title":"Inhibition of nucleotide pyrophosphatase\/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug","volume":"57","author":"Danino","year":"2018","journal-title":"Rheumatology"},{"issue":"46","key":"10.1016\/j.berh.2021.101720_bib35","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1039\/C9OB02199J","article-title":"Adenine-(methoxy)-ethoxy-P\u03b1,\u03b1-dithio-triphosphate inhibits pathologic calcium pyrophosphate deposition in osteoarthritic human chondrocytes","volume":"17","author":"Nassir","year":"2019","journal-title":"Org Biomol Chem"},{"issue":"SUPPL 2","key":"10.1016\/j.berh.2021.101720_bib36","first-page":"36","article-title":"A\u00a0scoping review and content analysis of outcome domains reported in CPPD clinical studies","volume":"50","author":"Cai","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.berh.2021.101720_bib37","article-title":"Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): item generation and item reduction","author":"Tedeschi","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:07Z","timestamp":1761499327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521694221000620"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101720","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium pyrophosphate deposition (CPPD) disease \u2013 Treatment options","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101720"}}